A Registry of Treatment Adherence for Patients With Schizophrenia

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second generation (atypical) antipsychotic medications.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen-Cilag, S.A.
• Treatments: Antipsychotic Agents

Criteria

Inclusion Criteria:

• Patients starting treatment with a new antipsychotic medication, in accordance with product labeling in the local country

• Permitted by their physician and by the patient to participate in a clinical trial

Exclusion Criteria:

• Patients not meeting all of the inclusion criteria for entry into the study